Ra Pharmaceuticals (NASDAQ:RARX) Posts Earnings Results, Beats Expectations By $0.03 EPS

Ra Pharmaceuticals (NASDAQ:RARX) issued its quarterly earnings results on Wednesday, March 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.03, Bloomberg Earnings reports.

NASDAQ RARX opened at $5.51 on Friday. The stock has a market capitalization of $180.48, a PE ratio of -2.29 and a beta of 2.31. Ra Pharmaceuticals has a 12 month low of $4.78 and a 12 month high of $27.84.

How to Become a New Pot Stock Millionaire

A number of brokerages have recently commented on RARX. Zacks Investment Research lowered shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Credit Suisse Group restated an “outperform” rating and set a $16.00 target price on shares of Ra Pharmaceuticals in a research report on Thursday, January 18th. ValuEngine downgraded shares of Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. BMO Capital Markets lowered their target price on shares of Ra Pharmaceuticals from $34.00 to $31.00 and set an “outperform” rating on the stock in a report on Thursday, March 15th. Finally, SunTrust Banks reaffirmed a “buy” rating on shares of Ra Pharmaceuticals in a research note on Thursday, March 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $19.50.

In other news, major shareholder Ra Capital Healthcare Fund Lp purchased 2,500,000 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was acquired at an average cost of $6.00 per share, with a total value of $15,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Enterprise Associates 13 L. New purchased 2,000,000 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were purchased at an average cost of $6.00 per share, with a total value of $12,000,000.00. The disclosure for this purchase can be found here. Corporate insiders own 14.50% of the company’s stock.

An institutional investor recently raised its position in Ra Pharmaceuticals stock. State Street Corp lifted its stake in Ra Pharmaceuticals Inc (NASDAQ:RARX) by 40.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 151,063 shares of the company’s stock after purchasing an additional 43,376 shares during the quarter. State Street Corp owned about 0.67% of Ra Pharmaceuticals worth $2,830,000 as of its most recent SEC filing. Institutional investors and hedge funds own 47.86% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Ra Pharmaceuticals (NASDAQ:RARX) Posts Earnings Results, Beats Expectations By $0.03 EPS” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/ra-pharmaceuticals-rarx-posts-quarterly-earnings-results.html.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Earnings History for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply